PTC Therapeutics, Inc. Available-for-sale Securities, Gross Realized Gains
PTC Therapeutics, Inc. (PTCT) reported Available-for-sale Securities, Gross Realized Gains of $0 for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-09.
Discontinued › Income Statement › Other Income
us-gaap:AvailableForSaleSecuritiesGrossRealizedGains · last filed 2018-05-09
- PTC Therapeutics, Inc. available-for-sale securities, gross realized gains for the quarter ending 2018-03-31 was $0.00.
- PTC Therapeutics, Inc. available-for-sale securities, gross realized gains for the quarter ending 2017-12-31 was -$30.00K.
- PTC Therapeutics, Inc. available-for-sale securities, gross realized gains for the quarter ending 2017-09-30 was $0.00.
| Period end | Available-for-sale Securities, Gross Realized Gains 3 month | Available-for-sale Securities, Gross Realized Gains 6 month | Available-for-sale Securities, Gross Realized Gains 9 month | Available-for-sale Securities, Gross Realized Gains 12 month |
|---|---|---|---|---|
| 2018-03-31 | $0.00 10-Q · filed 2018-05-09 | -$30.00K derived: sum of 2 quarters · filed 2018-05-09 | -$30.00K derived: sum of 3 quarters · filed 2018-05-09 | |
| 2017-12-31 | -$30.00K derived: 10-Q 12 month − 10-Q 9 month · filed 2018-05-09 | -$30.00K derived: sum of 2 quarters · filed 2018-05-09 | $0.00 10-Q · filed 2018-05-09 | |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-02 | $30.00K 10-Q · filed 2017-11-02 | ||
| 2017-06-30 | $30.00K 10-Q · filed 2017-08-09 | |||
| 2016-12-31 | $0.00 10-Q · filed 2017-11-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |